The Latest Breaking News from Pfizer

The stock market rallied this week, with the Nasdaq regaining its 50-day on a semi-dovish Fed, a tame jobs report and a huge Apple buyback.

Amid increasing healthcare spending, breakthroughs in genomics and personalized medicine, and the adoption of new technologies, the pharma industry is booming. So, let’s analyze Eli Lilly (LLY) and Pfizer (PFE) to determine which pharma stock will surge from their first-quarter earnings. Read on to find out.

June S&P 500 E-Mini futures (ESM24) are down -0.42%, and June Nasdaq 100 E-Mini futures (NQM24) are down -0.73% this morning as mixed earnings and the prospect of higher-for-longer U.S. interest rates weighed on sentiment, with all eyes on the Federal Reserve’s interest rate decision due later in the day.

June S&P 500 E-Mini futures (ESM24) are down -0.29%, and June Nasdaq 100 E-Mini futures (NQM24) are down -0.58% this morning as the prospect of higher-for-longer U.S. interest rates continued to weigh on sentiment, with all eyes on the Federal Reserve’s interest rate decision due later in the day.

June S&P 500 E-Mini futures (ESM24) are down -0.29%, and June Nasdaq 100 E-Mini futures (NQM24) are down -0.58% this morning as the prospect of higher-for-longer U.S. interest rates continued to weigh on sentiment, with all eyes on the Federal Reserve’s interest rate decision due later in the day.

The FDA approved Pfizer's hemophilia gene therapy on Friday. But Pfizer stock only inched ahead on the approval early Friday.

Analysts at Goldman Sachs think these 5 underperforming stocks could be poised to outperform, thanks to a healthy valuation discount and expected EPS growth.

Most of the largest pharmaceutical companies report losing money in the United States, despite the majority of their sales coming from Americans. The result is lower U.S. taxes for the companies.

Some 75 per cent of Australians at higher risk of serious illness from COVID-19 do not have a plan to manage the potentially-lethal virus, new research shows.